Cancer Treatment in Korea: A Complete Guide

South Korea ranks among the top five countries globally for cancer survival rates, with outcomes that match or exceed those of the United States, Japan, and Western Europe — at a fraction of the cost. For international patients facing a cancer diagnosis, Korean oncology offers a combination of advanced treatment modalities, high surgical volume, advanced clinical trials, and pricing that is typically 30-60% lower than equivalent care in the US.

This is not a guide that oversimplifies cancer treatment or promises easy answers. Cancer is complex, treatment decisions are deeply personal, and no hospital — however excellent — can guarantee outcomes. What we can provide is factual information about Korea’s cancer treatment capabilities, specific hospital strengths, realistic cost ranges, and practical guidance for international patients considering treatment in Korea.

Korea’s Cancer Survival Rates: The Data

Korea’s cancer survival rates are among the highest in the world, driven by aggressive early screening programs, high-volume surgical expertise, and rapid adoption of new treatment technologies.

Five-year relative survival rates for common cancers (Korean National Cancer Institute data, 2017-2021 diagnosis period):

The standout figures are stomach cancer (77.5% vs 35.7%) and liver cancer (39.3% vs 22.3%). These dramatic differences are not because Korean oncologists are fundamentally superior to American ones — they reflect the power of early detection through Korea’s national screening programs and the resulting surgical experience with early-stage disease.

Treatment Modalities Available in Korea

Korean cancer centers offer the full range of modern oncology treatment modalities:

Surgery

Surgery remains the primary curative treatment for most solid tumors. Korean cancer surgeons operate in high-volume environments — a typical hepatobiliary surgeon at a major Korean hospital performs 200-400 liver resections per year, compared to 50-150 at a busy US academic center. This volume translates into lower complication rates and shorter hospital stays.

Minimally invasive surgery: Korean hospitals have been early and aggressive adopters of laparoscopic and robotic surgery for cancer. Robotic gastrectomy (stomach cancer), robotic prostatectomy, and robotic thyroidectomy are routine at major centers. Severance Hospital operates one of Asia’s largest robotic surgery programs.

Organ-sparing techniques: Korean surgeons are recognized for developing organ-preserving surgical approaches — endoscopic submucosal dissection (ESD) for early gastric cancer, breast-conserving surgery with oncoplastic techniques, and sphincter-sparing surgery for rectal cancer.

Chemotherapy

All standard chemotherapy regimens used internationally are available in Korea. Medication pricing is regulated by the Korean government, which means that chemotherapy drugs that cost thousands of dollars per infusion in the US are available at a fraction of the price.

Example pricing comparisons for common chemotherapy drugs:

These price differences apply to the same branded drugs from the same manufacturers. Korea also has access to biosimilars — biologically equivalent versions of brand-name biologics — which further reduce costs. Samsung Bioepis and Celltrion, both Korean companies, are among the world’s largest biosimilar manufacturers.

Radiation Therapy

Korean cancer centers operate the full range of radiation modalities:

• Intensity-modulated radiation therapy (IMRT)
• Volumetric modulated arc therapy (VMAT)
• Stereotactic body radiation therapy (SBRT): Precisely targeted high-dose radiation for small tumors, particularly effective for lung and liver metastases
• Stereotactic radiosurgery (SRS): For brain metastases and primary brain tumors
• Brachytherapy: Internal radiation for cervical, prostate, and other cancers

Proton Therapy

Proton therapy is an advanced form of radiation that delivers targeted beams with minimal damage to surrounding tissue. It is particularly valuable for:

• Pediatric cancers (reduces long-term radiation side effects in growing children)
• Brain and spinal cord tumors
• Skull base tumors
• Liver cancer (when surgery is not feasible)
• Prostate cancer (reduced bowel and bladder side effects)
• Re-irradiation of previously treated areas

Korea operates three proton therapy centers:

1. National Cancer Center (NCC) in Goyang — Korea’s first proton center, operational since 2007
2. Samsung Medical Center in Seoul — Opened 2015, treats high volumes of liver and prostate cancer
3. Severance Hospital (Yonsei) — Proton therapy available through their radiation oncology department

In the US, a full course of proton therapy costs $50,000-$150,000. In Korea, the same treatment typically costs $20,000-$50,000.

Immunotherapy

Korea has been an early adopter of cancer immunotherapy, including:

• Checkpoint inhibitors: Pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq), durvalumab (Imfinzi) — all approved and available
• Combination immunotherapy regimens: Ipilimumab + nivolumab for melanoma, renal cell carcinoma, and other cancers
• Immunotherapy + chemotherapy combinations: Standard of care for many advanced cancers

Korean oncologists are active participants in global immunotherapy clinical trials, meaning patients may have access to investigational immunotherapy agents not yet available in their home countries.

CAR-T Cell Therapy

Chimeric antigen receptor T-cell (CAR-T) therapy is a revolutionary treatment for certain blood cancers. The patient’s own T-cells are genetically engineered to recognize and destroy cancer cells.

Seoul St. Mary’s Hospital is Korea’s leader in CAR-T therapy, with its Catholic Hematology Hospital performing CAR-T for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and B-cell acute lymphoblastic leukemia (B-ALL).

In the US, CAR-T therapy (Kymriah or Yescarta) costs $373,000-$475,000 for the infusion alone, with total treatment costs often exceeding $1 million when hospitalization and complication management are included. Korean pricing is substantially lower, though still a significant investment.

Targeted Therapy

Korean cancer centers prescribe the full range of targeted therapies based on genomic profiling:

• Next-generation sequencing (NGS) panels: Full genomic profiling of tumors to identify actionable mutations
• Targeted agents: Erlotinib, osimertinib (EGFR-mutated lung cancer), imatinib (CML, GIST), vemurafenib (BRAF-mutated melanoma), olaparib (BRCA-mutated breast/ovarian cancer), and dozens more
• Companion diagnostics: Korean pathology labs perform all standard molecular tests (EGFR, ALK, ROS1, BRAF, HER2, PD-L1, MSI, TMB) to guide targeted therapy selection

Partner Hospital Cancer Specialties

Seoul St. Mary’s Hospital

Seoul St. Mary’s is Korea’s premier center for blood cancers and bone marrow transplant:

• 5 BMT center globally with 30,000+ transplants performed

• Catholic Hematology Hospital: Dedicated facility for leukemia, lymphoma, myeloma, MDS
• CAR-T cell therapy program
• Haploidentical transplant pioneer in Asia
• Solid tumor oncology: Also strong in breast, colorectal, and gynecologic cancers
• Newsweek #108 globally

Best for: Leukemia, lymphoma, multiple myeloma, MDS, any blood cancer requiring transplant.

Severance Hospital (Yonsei University)

Severance Hospital is Korea’s most internationally recognized hospital and a top-tier cancer center:

• Newsweek #40 globally
• Yonsei Cancer Center: Multidisciplinary tumor boards for every cancer type
• Proton therapy access through the radiation oncology department
• Robotic surgery program: One of Asia’s largest, used extensively for prostate, gastric, colorectal, and gynecologic cancers
• Clinical trials: Extensive phase I-III trial program, particularly in lung cancer, GI cancers, and immunotherapy
• First JCI-accredited hospital in Korea

Best for: Complex multi-specialty cancer cases, lung cancer, GI cancers, prostate cancer, brain tumors, and patients seeking access to clinical trials.

Korea University Anam Hospital

KU Anam provides full-spectrum cancer care with particular strength in:

• GI cancers: Gastric, colorectal, hepatobiliary
• 5x JCI accredited: Consistent quality and patient safety
• Organ transplant: Relevant for liver cancer patients who may need transplant
• 838 beds with a dedicated cancer center

Best for: GI cancers, liver cancer (especially when transplant is a consideration), patients who want JCI-accredited care in a mid-sized hospital setting.

Bucheon St. Mary’s Hospital

Bucheon St. Mary’s has earned HIRA Grade 1 ratings for four cancers, making it one of Korea’s top-performing cancer centers by measured outcomes:

• HIRA Grade 1: Stomach cancer, colorectal cancer, lung cancer, breast cancer
• Russian-licensed physicians: On-staff doctors licensed to practice in Russia, facilitating communication with Russian-speaking patients
• Proximity to Incheon Airport: 30 minutes, significantly closer than central Seoul hospitals
• Lower price point than Seoul hospitals with comparable outcomes for its top-rated cancers

Best for: Stomach, colorectal, lung, and breast cancer treatment for budget-conscious patients or Russian-speaking patients. Excellent for cancer screening and early detection.

Cost Comparison: Cancer Treatment in Korea vs the US

Cancer treatment costs vary enormously based on cancer type, stage, treatment plan, and complications. The following are representative ranges:

These figures demonstrate that Korea typically offers 50-70% savings compared to US cancer treatment. For treatment plans extending over months or years (as many cancer protocols do), the cumulative savings can be hundreds of thousands of dollars.

Clinical Trials

Korea is a major participant in global oncology clinical trials. The Korean Cancer Study Group (KCSG) coordinates multi-center trials across the country, and individual hospitals run their own investigator-initiated studies.

Why this matters for international patients:

• Access to investigational drugs: Clinical trials may offer access to treatments not yet approved in your home country
• Reduced cost: Trial participants often receive the investigational drug and related monitoring at no cost
• Latest treatments: Trial participation means treatment at the forefront of oncology research

Major clinical trial areas in Korean oncology include:

• EGFR-mutated and ALK-positive non-small cell lung cancer
• Advanced gastric cancer (Korea’s high incidence drives strong trial activity)
• Hepatocellular carcinoma (liver cancer)
• CAR-T and other cellular therapies for blood cancers
• Novel immunotherapy combinations
• Biomarker-driven precision oncology

To explore clinical trial options, patients can work with their Korean oncologist or search ClinicalTrials.gov with Korean hospital names as study sites.

The International Patient Process for Cancer Treatment

Step 1: Medical Record Review

Before traveling, submit your complete medical records to the hospital’s international patient center:

• Pathology reports (including molecular/genomic testing results)
• Imaging (CT, MRI, PET-CT on CD/DVD or via secure transfer)
• Treatment history (surgery reports, chemotherapy records, radiation plans)
• Current medications
• Physician referral letter (if available)

The Korean oncology team reviews these records and provides a preliminary treatment recommendation and cost estimate, typically within 5-10 business days.

Step 2: Second Opinion (Optional but Recommended)

Many international patients come to Korea specifically for a second opinion on their treatment plan. Korean oncologists may confirm your current plan, suggest modifications, or recommend alternative approaches. A second opinion consultation typically costs $200-$500 and can be done via telemedicine before traveling.

Step 3: Travel and Initial Consultation

Upon arrival, you will meet with your oncologist for a thorough in-person evaluation. Additional diagnostic tests may be ordered — repeat imaging to assess current disease status, new biopsies for updated molecular profiling, or additional blood work. Korean hospitals can perform most diagnostic workups within 3-5 business days.

Step 4: Multidisciplinary Tumor Board

At major Korean cancer centers, your case will be presented to a multidisciplinary tumor board — a panel of oncologists, surgeons, radiation oncologists, pathologists, and radiologists who collectively review your case and agree on the optimal treatment plan. This is standard practice at Severance, Seoul St. Mary’s, and KU Anam.

Step 5: Treatment

Treatment proceeds according to the agreed plan. Depending on your cancer type and stage, this may involve:

• Surgery followed by adjuvant chemotherapy (weeks to months)
• Neoadjuvant chemotherapy followed by surgery (months)
• Radiation therapy (daily sessions over 5-7 weeks)
• Immunotherapy infusions (every 2-3 weeks, potentially for 1-2 years)
• Combination approaches

Step 6: Follow-Up and Transition Home

Before returning home, you will receive:

• Complete medical records in English
• Detailed treatment summary for your home oncologist
• Follow-up schedule and monitoring plan
• Prescription information for ongoing medications
• Communication channel with your Korean medical team for questions

For ongoing treatments (immunotherapy, oral targeted therapy), coordination between your Korean and home-country oncologists ensures continuity.

Practical Considerations

Length of stay: Varies enormously by treatment. A cancer screening and second opinion may require only 1-2 weeks. Surgery with recovery: 2-4 weeks. Chemotherapy courses: weeks to months, with the possibility of returning home between cycles. BMT: 2-4 months minimum.

Accommodation: For extended cancer treatment, serviced apartments near the hospital are the practical choice. Many hospitals maintain lists of recommended accommodations for international patients. Budget $60-$150/night for a furnished apartment.

Caregiver/companion: Cancer treatment is physically and emotionally demanding. Having a companion — spouse, family member, or friend — is strongly recommended for surgical patients and essential for transplant patients.

Insurance: Some international health insurance plans cover overseas cancer treatment, particularly at JCI-accredited hospitals. Contact your insurer before committing to treatment. Korean hospitals can provide detailed invoices formatted for insurance reimbursement claims.

Health screening: If you are visiting Korea and want to ensure thorough baseline screening alongside your cancer treatment, consider adding a health checkup to your visit.

Facing a cancer diagnosis and exploring treatment options in Korea? Our Seoul-based team coordinates with Korea’s top cancer centers to help international patients access world-class oncology care. We provide free initial consultations and manage all logistics.

Talk to Our Team →